LatchBio
Provides biocomputational infrastructure to accelerate laboratory data analysis workflows.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- Bioinformatics platform
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- San Francisco, United States
- Region
- North America
- Founded
- 2021
- Total funding
- $33M
What they do
Latch lets biologists run bioinformatics tools and pipelines on large experimental datasets without writing code. Its cloud software supports uploading, organising and analysing genomic sequencing data for biotechnology companies and academic laboratories, and is free for academics. The company raised a $28 million Series A in June 2022, co-led by Coatue and Lux Capital.
Leadership & founders
Leadership as of 14 November 2026.
- Alfredo Andere
Co-founder and CEO
- Kenny Workman
Co-founder and CTO
- Kyle Giffin
Co-founder and COO
Investors
- Coatue
- Lux Capital
- Hummingbird Ventures
- Y Combinator
- Caffeinated Capital
- Haystack
- Fifty Years
History and progression
How LatchBio got here, step by step.
2 June 2022
$28 million Series A
Co-led by Coatue and Lux Capital with Hummingbird Ventures, Caffeinated Capital, Haystack and Fifty Years.
Key products
- Latch platform
- Code-free cloud platform for biologists to run bioinformatics tools and pipelines on large experimental datasets; free for academics
Recent news
2 June 2022
TechCrunch: LatchBio raises $28M
Related companies
Your daily HealthTech Signal
No hype. Just signal.
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: